Kavanaugh A - Search Results

1

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB; PSUMMIT-1 and 2 Study Groups. Kavanaugh A, et al. Ann Rheum Dis. 2014 Jun;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741. Epub 2014 Feb 19. Ann Rheum Dis. 2014. PMID: 24553909 Free PMC article. Clinical Trial.

2

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial.

Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Mocci S. Kavanaugh A, et al. J Rheumatol. 2003 Mar;30(3):449-54. J Rheumatol. 2003. PMID: 12610799 Clinical Trial.

3

Pharmacological treatment of established rheumatoid arthritis.

Lee SJ, Kavanaugh A. Lee SJ, et al. Among authors: kavanaugh a. Best Pract Res Clin Rheumatol. 2003 Oct;17(5):811-29. doi: 10.1016/s1521-6942(03)00048-2. Best Pract Res Clin Rheumatol. 2003. PMID: 12915159 Review.

4

Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis.

Kavanaugh A, Han C, Bala M. Kavanaugh A, et al. J Rheumatol. 2004 May;31(5):849-55. J Rheumatol. 2004. PMID: 15124242

5

Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.

Bieber J, Kavanaugh A. Bieber J, et al. Among authors: kavanaugh a. Rheum Dis Clin North Am. 2004 May;30(2):257-70, v. doi: 10.1016/j.rdc.2004.01.003. Rheum Dis Clin North Am. 2004. PMID: 15172039 Review.

6

Outcome measures in psoriatic arthritis.

Kavanaugh A, Cassell S. Kavanaugh A, et al. Curr Rheumatol Rep. 2005 Jun;7(3):195-200. doi: 10.1007/s11926-996-0039-x. Curr Rheumatol Rep. 2005. PMID: 15918995 Review.

7

Outcome measures in psoriatic arthritis.

Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, Kavanaugh AF, Nash P, Ritchlin CT, Strand CV, Taylor W. Gladman DD, et al. J Rheumatol. 2005 Nov;32(11):2262-9. J Rheumatol. 2005. PMID: 16265714

8

The pharmacoeconomics of newer therapeutics for rheumatic diseases.

Kavanaugh A. Kavanaugh A. Rheum Dis Clin North Am. 2006 Feb;32(1):45-56, viii. doi: 10.1016/j.rdc.2005.09.003. Rheum Dis Clin North Am. 2006. PMID: 16504820 Review.

9

Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.

Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guideline Committee. Kavanaugh AF, et al. J Rheumatol. 2006 Jul;33(7):1417-21. Epub 2006 May 15. J Rheumatol. 2006. PMID: 16724373 Review.

10

Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis.

Kavanaugh A. Kavanaugh A. Adv Ther. 2006 Mar-Apr;23(2):208-17. doi: 10.1007/BF02850127. Adv Ther. 2006. PMID: 16751154 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

584 results

Search Page

Filters